



IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE

PATENT -

TECH CENTER 1600/2900

OCT 17 2001

RECEIVED

#5

11/14/01

Applicants:

ANDREI V. GUDKOV ET AL.

Serial No.: 09/880,417

Filed: June 13, 2001

For: p53 INHIBITORS AND
THERAPEUTIC USE OF THE SAME


Attorney Docket No. 27611/37477

Group Art Unit: 1614

Examiner: Unassigned

) I hereby certify that this
) paper is being deposited with
) the United States Postal
) Service with sufficient
) postage as first class mail in
) an envelope addressed to:
) Assistant Commissioner for
) Patents, Washington, D.C.
) 20231 on this date:

) October 10, 2001

) 
) James J. Napoli
) Registration No. 32,361
) Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents
Washington, D.C. 20231

Sir:

Pursuant to their duty of disclosure under 37 C.F.R. §1.56, applicants hereby bring to the examiner's attention patents and publications that may be material to the examination of the above-identified application. Therefore, in compliance with 37 C.F.R. §1.97 and §1.98, applicants enclose a completed Form PTO-1449 listing the possibly pertinent patents and publications.

In accordance with 37 C.F.R. §1.98(d), copies of the patents and publications are not enclosed herein because copies were provided in a prior application that applicants rely upon for an earlier filing date under 35 U.S.C. §120. Copies of documents listed in the attached

Form PTO-1449 were provided to, or cited by, the examiner of the following pending patent application:

Andrei V. Gudkov et al.
Serial No. 09/493,527
Filing Date: January 28, 2000.

If the examiner needs a new copy of a patent or publication listed on the enclosed Form PTO-1449, applicants can provide such a copy.


This Information Disclosure Statement is submitted more than three months after the filing date of the above-identified application, and, to applicants' knowledge, before the mailing date of a first Office Action on the merits. Therefore, under 37 C.F.R. §1.97(b), this Information Disclosure Statement shall be considered by the Patent Office.

The Commissioner, however, is hereby authorized to charge any fee which may be required during the pendency of this application under 37 C.F.R. 1.16 or 37 C.F.R. 1.17 to Deposit Account No. 13-2855. A duplicate copy of this Transmittal is enclosed herewith.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN

By



James J. Napoli
(Registration No. 32,361)
Attorneys for Applicants
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606
(312) 474-6300

Chicago, Illinois
October 10, 2001